Authors: Dowlati, A Hoppel, CL Ingalls, ST Majka, S Li, XL Sedransk, N Spiro, T Gerson, SL Ivy, P Remick, SC

Citation: A. Dowlati et al., Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days, J CL ONCOL, 19(8), 2001, pp. 2309-2318

Authors: Dowlati, A Levitan, N Gordon, NH Hoppel, CL Gosky, DM Remick, SC Ingalls, ST Berger, SJ Berger, NA

Citation: A. Dowlati et al., Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer, CANC CHEMOT, 47(2), 2001, pp. 141-148

Authors: Rose, PG Gordon, NH Fusco, N Fluellen, L Rodriguez, M Ingalls, ST Hoppel, CL

Citation: Pg. Rose et al., A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma, GYNECOL ONC, 78(2), 2000, pp. 228-234

Authors: Spiro, TP Gerson, SL Liu, LL Majka, S Haaga, J Hoppel, CL Ingalls, ST Pluda, JM Willson, JKV

Citation: Tp. Spiro et al., O-6-benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directrd DNA repair, CANCER RES, 59(10), 1999, pp. 2402-2410